BT-001 (TG6030) Alone and With Pembrolizumab in Advanced Solid Tumors

Phase 2, open-label trial of udifitimod in soft tissue sarcoma (STS), bone cancer, Merkel cell carcinoma (MCC) and 3 more (2 arms), sponsored by Transgene SA. Primary endpoints: Overall incidence of adverse events (AEs), dose-limiting toxicities (DLTs), and serious adverse events (SAEs) in Phase I, Progression-free rate at 6 months (soft tissue sarcoma cohort, Phase IIa) and 1 more. Started Dec 2024; status: completed.